Small Molecule Drug Development for Stroke

Small molecules are considered to be low molecular weight organic compounds, less than 900 Da (900 g/mol). Many small molecule drugs have been identified, characterized, and critically evaluated in stroke pathology injury due to their membrane permeability and specificity for the protein or process of interest. Based on a growing understanding of the pathophysiological pathways of stroke, small molecules have been developed to interfere with the ischemic cascade, which can attenuate thrombosis, ischemia-induced excitotoxicity, mitochondrial damage and inflammation.

Our Small Molecule Drug Development Services for Stroke

Ace Therapeutics helps clients develop high-quality small molecule drugs for stroke. Our services cover all stages from target identification to preclinical evaluation.

Target Identification. We provide molecular biology and structural biology technology platforms for target-based small molecule drug discovery for stroke.
Target Screening and Lead Compound Optimization. We can perform target-based high-throughput screening and obtain composite crystal structures of small molecules for rational optimization with computer assistance.
Preclinical Evaluation of Small Molecules for stroke. We use cell-based assays and animal models of stroke to evaluate the therapeutic potential of small molecule drugs in terms of neuroprotection, reduction of blood-brain barrier disruption, modulation of inflammatory responses, and improvement of functional outcomes.

Antiplatelet Drug Development for Stroke

Cyclooxygenase inhibitors
Phosphodiesterase inhibitors
ADP receptor antagonists
Membrane protein IIb/IIIa (GP IIb/IIIa) receptor antagonists
Adenosine receptor antagonists
5-hydroxytryptamine (5-HT) receptor antagonists

Why Choose Us

We have technology platforms for high-throughput screening, virtual screening, and structure- and fragment-based drug design.
We have reliable and extensive in vitro and animal models of stroke.
We have an extensive library of compounds for screening.
We offer mass spectrometry (MS), nuclear magnetic resonance (NMR), gene sequencing, proteomics and other technologies to help you discover new targets.
We design customized small molecule drug development programs for clients based on specific therapeutic targets.

Ace Therapeutics is committed to helping clients accelerate the development of small molecule drugs for stroke. Our team collaborates with leading academic and pharmaceutical partners to design and execute well-controlled preclinical studies. Please contact us for more information. We look forward to working with you!

Reference

Goenka, L., et al. (2019). Neuroprotective agents in acute ischemic stroke—a reality check. Biomedicine & Pharmacotherapy, 109, 2539-2547.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.